Birmingham Hip Resurfacing — Cost, Top Hospitals & Success Rates | MyMedicPlus

Birmingham Hip Resurfacing (BHR) is a specialised bone-conserving hip procedure that preserves the patient's femoral neck and head by covering the damaged femoral head with a precision-manufactured metal cap (femoral component) and replacing the worn acetabular socket with a metal cup — resulting in a metal-on-metal (MoM) bearing couple. It was developed by Derek McMinn in Birmingham, UK, in the 1990s and represents a major advance over conventional total hip replacement (THR) in selected patients because it preserves the proximal femoral bone stock, making future revision surgery technically easier if needed.

Unlike total hip replacement, which removes the entire femoral head and neck and inserts a long metal stem down the femoral canal, BHR retains the femoral head skeleton and uses it as the foundation for the metal cap. The femoral head is precisely machined on a computer-controlled lathe to a spherical shape, and the metal cap is cemented in place with bone cement. The acetabular cup is press-fitted without cement. The result is a near-normal femoral anatomy and a large femoral head diameter (matching or close to the patient's natural head size) that provides excellent hip stability, natural gait mechanics, and a substantially lower dislocation risk than conventional THR with its smaller head diameter.

BHR is performed through a standard posterior or anterolateral hip approach and requires an experienced surgeon trained in hip resurfacing technique. The surgery typically takes 1.5–2.5 hours under general or spinal anaesthesia. Patients are mobilised on the day of surgery or the day after, initially with walking aids, and typically discharged within 2–4 days.

The principal indication for Birmingham Hip Resurfacing is severe hip osteoarthritis — characterised by cartilage loss, subchondral sclerosis, osteophyte formation, and hip pain with functional limitation not adequately controlled by conservative measures including analgesics, physiotherapy, intra-articular injections, and lifestyle modification. BHR is preferred over total hip replacement specifically in young active patients (typically under 60 years) who are likely to outlive a conventional hip implant and would otherwise require a revision procedure during their lifetime.

Other indications include avascular necrosis (osteonecrosis) of the femoral head in stages where the femoral head shape is largely preserved, post-traumatic arthritis after acetabular or femoral neck fractures that have healed but left articular incongruity, and sequelae of childhood hip conditions such as Perthes disease or developmental dysplasia of the hip, where the native femoral head has undergone deformity but the bone stock is preserved. Hip dysplasia requiring acetabular reconstruction may be combined with resurfacing at centres with specialist expertise.

Ideal candidates for BHR are male patients (male sex is a positive predictor of outcome), aged under 60, with a large femoral head size (head diameter above 46–48 mm), good bone quality, and severe hip arthritis causing unacceptable pain and functional limitation. Large femoral head size matters because smaller femoral heads are associated with higher rates of femoral neck fracture after resurfacing — the most serious early complication. MRI assessment of the femoral head for cystic changes and bone quality is routinely performed pre-operatively, as large femoral head cysts significantly increase fracture risk and may prompt conversion to conventional THR.

Contraindications include female sex (women have a significantly higher revision rate than men due to smaller head sizes, and MHRA/FDA guidance recommends against BHR in most women), severe osteoporosis (poor bone quality insufficient to support the cemented femoral component), active metal allergy or hypersensitivity to cobalt or chromium (key components of the metal bearing), renal impairment (impaired clearance of metal ions), significant femoral head cysts occupying more than 30% of head volume, deformity precluding adequate femoral head preparation, and prior inflammatory arthritis where bone stock is often compromised.

The Birmingham Hip Resurfacing system (Smith & Nephew) is the original and most extensively studied resurfacing system with over 25 years of clinical data. Other resurfacing systems including the Cormet, Conserve Plus, and ASR (now withdrawn) have been used. The BHR specifically has the strongest long-term registry data — the National Joint Registry (NJR) of England and Wales reports 10-year implant survival of approximately 96% in males aged under 65 with large head sizes.

Surgical approach options include the posterior approach (most common, with posterior capsule repair to prevent posterior dislocation), the anterolateral approach (Watson-Jones), and the direct anterior approach at centres experienced with this route. Operative technique is demanding compared with standard THR: the precision of femoral head preparation, varus-valgus alignment of the femoral component (optimal 130–140 degrees stem-shaft angle), and acetabular cup positioning are critical to outcome. All BHR candidates should be operated on by surgeons who perform at least 30–50 hip resurfacings per year, as volume-outcome relationships are established. Computer-assisted navigation or robotic arm assistance is increasingly used to optimise component positioning.

Selecting the most appropriate Birmingham Hip Resurfacing approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

BHR provides outstanding functional outcomes in appropriately selected patients. The large femoral head diameter (matching native anatomy) gives excellent hip stability with very low dislocation rates (approximately 0.5–1% versus 2–4% for conventional THR). Preservation of the femoral neck and proximal femoral bone stock means that if revision is ultimately needed, it can be performed with standard primary THR techniques rather than complex revision implants. Proprioceptive preservation (the femoral neck's mechanoreceptors are preserved) may contribute to the natural gait pattern and confidence with high-demand activities reported by resurfacing patients.

Outcome data from the UK NJR demonstrate 10-year survival of 96% for BHR in male patients aged under 65, comparable to or better than some conventional THR systems in the same age group. Patients consistently report high satisfaction, ability to return to sport and high-demand activities (running, cycling, skiing, golf), and excellent hip function scores. The BHR is specifically associated with high patient satisfaction scores compared with conventional THR in young active males.

The primary early complication specific to hip resurfacing is femoral neck fracture, occurring in approximately 1–2% of cases. This is more common in small femoral head sizes, notching of the femoral neck during preparation, large femoral head cysts, and early unrestricted weight-bearing. Most femoral neck fractures are managed by conversion to total hip replacement. Avascular necrosis of the resurfaced femoral head, though uncommon, can occur if the surgical technique disrupts blood supply.

The most important long-term concern specific to metal-on-metal hip resurfacing is adverse local tissue reactions (ALTR) caused by cobalt-chromium ion release from the metal bearing surface. Metal wear particles can cause pseudotumours — periprosthetic soft tissue masses of varying severity — and local tissue necrosis in a subset of patients. MHRA and FDA guidance requires regular blood metal ion monitoring (cobalt and chromium serum levels) and MRI MARS surveillance in all BHR patients. Patients with consistently elevated metal ions or imaging abnormalities may require early revision. Systemic metal ion exposure is a concern in patients with renal impairment. These metal ion issues specifically affect female patients more than males and are a principal reason BHR is now primarily recommended for males.

Patients are mobilised on the day of surgery or within 24 hours, with partial weight-bearing on crutches for 6 weeks transitioning to full weight-bearing. Hip precautions (avoiding deep flexion beyond 90 degrees, crossing legs) are less restrictive with BHR than conventional THR due to the large femoral head diameter providing natural stability. Physiotherapy focuses on hip abductor and quadriceps strengthening, gait normalisation, and progressive activity increase.

Return to driving is typically at 6 weeks. Most patients return to light work at 6–8 weeks and sedentary work earlier. Return to sport — including running, cycling, and low-impact activities — is typically at 3–6 months, with high-impact activities after 6–12 months as decided by the surgeon. Annual blood cobalt and chromium ion monitoring is required for life, with serum cobalt above 2–3 ppb (micrograms per litre) triggering MRI MARS evaluation of periprosthetic soft tissues. Annual follow-up appointment with clinical assessment and X-ray is standard. Long-term NJR data registration is mandatory.

Birmingham Hip Resurfacing is a specialist procedure with higher implant and surgical costs than standard THR due to the precision engineering of the resurfacing components and the specialist surgical training required. In the United States, total cost of BHR including surgery, anaesthesia, implant, and hospital stay is approximately USD 30,000–50,000. In the UK, BHR is available through the NHS at specialist centres; private surgery costs GBP 12,000–20,000.

Medical tourists seeking BHR at lower cost most commonly travel to India, where specialist hip resurfacing is available at JCI-accredited orthopaedic centres in Bangalore, Mumbai, Chennai, and Hyderabad at costs of USD 5,000–10,000 all-inclusive — a saving of 75–85% versus US prices. Apollo Hospitals, Fortis Healthcare, and Manipal Hospitals have experienced hip resurfacing surgeons with access to the original BHR implant system. Thailand (Bumrungrad, Bangkok Hospital) and Turkey are further alternatives at USD 8,000–15,000. Ensuring the surgeon's specific BHR training and volume (minimum 50 procedures per year) is as important as cost in selecting an international centre.

Total hip replacement (conventional THR) with a ceramic-on-polyethylene or ceramic-on-ceramic bearing is the alternative for patients who are not suitable for or who choose not to have BHR. Modern cementless THR with highly cross-linked polyethylene or ceramic bearings also shows excellent longevity data (>95% at 15–20 years in NJR data) and avoids metal-on-metal bearing concerns. For most women and patients over 65, conventional THR is now preferred given BHR's poorer outcomes in these groups.

For milder arthritis not yet warranting joint replacement, non-surgical management (physiotherapy, analgesics, viscosupplementation injections, activity modification) and arthroscopic procedures for labral repair may provide medium-term symptom relief. Osteotomies (pelvic or femoral) in patients with dysplasia or femoroacetabular impingement without advanced cartilage loss can delay arthroplasty by 10–15 years in carefully selected younger patients. The decision between BHR and conventional THR should be made with an experienced hip surgeon who can review the patient's imaging, bone quality, femoral head size, and activity goals.